Nigeria Medical Cannabis Legalization: Policy, Progress & Regulatory Framework

Executive Summary

Nigeria is advancing toward medical cannabis legalization through legislative and regulatory reforms that could transform the country into a major player in Africa's emerging cannabis industry. In June 2026, the Nigerian National Assembly moved closer to passing comprehensive medical cannabis legislation, building on years of policy groundwork that began with the National Agency for Food and Drug Administration and Control (NAFDAC) establishing regulatory frameworks in 2022. The proposed legislation would permit cultivation, processing, and distribution of cannabis for medical and research purposes while maintaining strict prohibitions on recreational use. With a population exceeding 220 million people and significant agricultural capacity, Nigeria's entry into the legal medical cannabis market represents a watershed moment for both the continent's healthcare sector and the global cannabis industry. The legislation faces final parliamentary approval and presidential assent, with implementation expected to create thousands of jobs, attract foreign investment, and provide patients access to cannabis-based treatments for conditions including epilepsy, chronic pain, and cancer-related symptoms. Nigeria's approach balances international treaty obligations under the 1961 Single Convention on Narcotic Drugs with growing recognition of cannabis's therapeutic potential, positioning the nation as a potential regional hub for medical cannabis production and export.

Why This Matters

Nigeria's medical cannabis legalization affects 220 million citizens, positions Africa's largest economy as a continental cannabis hub, and opens a market projected to reach $7.1 billion by 2028. The stakes extend across multiple sectors. For patients, legalization means potential access to cannabis-based treatments currently unavailable through Nigeria's healthcare system, particularly for epilepsy patients who number an estimated 500,000 to 1 million nationwide according to the Epilepsy Society of Nigeria. Chronic pain sufferers, cancer patients undergoing chemotherapy, and individuals with treatment-resistant conditions stand to benefit from expanded therapeutic options. For Nigeria's agricultural sector, cannabis cultivation represents economic diversification beyond oil dependency. The country's tropical climate and existing agricultural infrastructure position it competitively for large-scale cultivation. Industry analysts project that legal cannabis could generate 150,000 to 250,000 direct jobs in cultivation, processing, and distribution within five years of implementation, with additional indirect employment in security, transportation, and ancillary services. International investors are monitoring Nigeria's progress closely. The country's regulatory framework could attract capital from established cannabis companies seeking African market entry, particularly those based in Canada, Israel, and Europe where medical cannabis markets are mature. Early-mover advantage in Nigeria could provide access to broader West African markets through the Economic Community of West African States (ECOWAS) framework. The legislation also carries implications for criminal justice reform. Cannabis-related arrests have burdened Nigeria's judicial system for decades, with the National Drug Law Enforcement Agency (NDLEA) reporting thousands of annual cannabis seizures. Medical legalization, while maintaining recreational prohibitions, represents a policy shift that acknowledges distinctions between medical and non-medical use.

Background and History

Nigeria's path toward medical cannabis legalization spans more than a decade of policy evolution, from strict prohibition to gradual regulatory acceptance of therapeutic applications.

Colonial Era and Early Prohibition (1935-1960)

Cannabis prohibition in Nigeria traces to British colonial administration. The Dangerous Drugs Ordinance of 1935 criminalized cannabis possession and cultivation, aligning Nigerian law with international prohibition efforts led by Western powers. This framework persisted through independence in 1960, with cannabis classified alongside heroin and cocaine despite its traditional use in some Nigerian communities for medicinal and cultural purposes.

Post-Independence Enforcement (1960-1990)

Following independence, Nigeria maintained strict cannabis prohibition. The Indian Hemp Act of 1966 specifically targeted cannabis, imposing severe penalties including lengthy prison sentences for cultivation and trafficking. The establishment of the NDLEA in 1989 intensified enforcement, with cannabis becoming the agency's primary focus. Throughout the 1980s and 1990s, Nigeria gained international attention as both a cannabis-producing nation and a transit point for drug trafficking, leading to diplomatic pressure and increased law enforcement cooperation with Western nations.

International Treaty Obligations and Domestic Policy (1990-2015)

As a signatory to the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, Nigeria faced constraints on cannabis policy reform. These treaties required maintaining criminal penalties for non-medical cannabis activities. However, the conventions explicitly permitted medical and scientific use under strict regulatory controls, creating the legal foundation for future medical cannabis programs. During this period, Nigerian cannabis policy remained static even as global attitudes began shifting. The NDLEA continued aggressive eradication campaigns, destroying thousands of hectares of illicit cannabis cultivation annually, particularly in states including Ondo, Edo, and Osun where climate and terrain favored cultivation.

Early Reform Discussions (2016-2019)

The first substantive policy discussions emerged in 2016 when members of the National Assembly began questioning whether Nigeria should explore medical cannabis. These conversations were influenced by international developments, particularly medical legalization in Canada, Israel, and numerous U.S. states. Nigerian medical professionals returning from training abroad brought knowledge of cannabis-based treatments, creating domestic pressure for policy reconsideration. In 2018, the House of Representatives Committee on Drugs, Narcotics and Financial Crimes held hearings on cannabis policy reform. Testimony from medical professionals, agricultural experts, and international consultants highlighted potential benefits of regulated medical cannabis. However, conservative opposition citing moral and religious concerns prevented legislative progress during this period.

NAFDAC Regulatory Framework Development (2020-2022)

A critical turning point came in January 2020 when NAFDAC, Nigeria's pharmaceutical and food regulatory authority, announced it would develop guidelines for medical cannabis regulation. This administrative action, which did not require legislative approval, signaled official recognition of cannabis's therapeutic potential. NAFDAC Director General Mojisola Adeyeye stated in 2020 that the agency was "working on guidelines that will regulate cannabis for medical purposes," according to statements reported by Nigerian media. The agency studied regulatory models from Canada, Israel, and Germany, adapting frameworks to Nigerian conditions. In May 2022, NAFDAC published draft regulations establishing pathways for cannabis-based medicine importation, clinical trials, and eventual domestic production. These regulations required products to meet pharmaceutical standards, contain specified cannabinoid ratios, and undergo rigorous testing. The framework created legal mechanisms for licensed entities to work with cannabis for medical purposes, effectively beginning Nigeria's medical cannabis program at the regulatory level.

Legislative Momentum (2023-2025)

Building on NAFDAC's regulatory foundation, legislative efforts accelerated in 2023. Senator Iroegbu Chuma introduced the Cannabis Control Bill in the Senate, proposing comprehensive medical cannabis legalization with strict cultivation licensing, product testing requirements, and physician prescription protocols. The bill drew on NAFDAC's regulatory work while establishing broader legal protections for patients, cultivators, and medical professionals. Parallel legislation emerged in the House of Representatives, where the Medical Cannabis Bill proposed similar frameworks with additional provisions for research institutions and export licensing. Throughout 2024, both chambers held committee hearings, receiving testimony from the Nigerian Medical Association, agricultural industry representatives, and international cannabis policy experts. Public opinion evolved during this period. Polling conducted by NOIPolls in 2024 indicated that 58 percent of Nigerians supported medical cannabis legalization, a significant increase from 34 percent in 2019. This shift reflected growing awareness of cannabis's medical applications and frustration with limited treatment options for chronic conditions.

2026 Legislative Progress

In June 2026, the National Assembly advanced medical cannabis legislation through critical procedural stages. The Senate passed its version of the Cannabis Control Bill on second reading, incorporating amendments that strengthened quality control requirements and established a dedicated Cannabis Regulatory Commission under the Federal Ministry of Health. The House of Representatives conducted parallel proceedings, with expectations that both chambers would reconcile differences and produce unified legislation for presidential consideration by late 2026.

Key Players

Nigeria's medical cannabis legalization involves government agencies, legislative champions, medical professionals, agricultural interests, and international stakeholders, each shaping policy outcomes.

National Agency for Food and Drug Administration and Control (NAFDAC)

NAFDAC has emerged as the primary regulatory architect of Nigeria's medical cannabis framework. The agency's pharmaceutical expertise and existing authority over controlled substances positioned it to develop technical regulations without awaiting legislative action. NAFDAC's 2022 guidelines established product standards, testing protocols, and licensing requirements that form the foundation of Nigeria's medical cannabis program. The agency will oversee product approvals, facility inspections, and quality assurance once full legalization occurs.

National Drug Law Enforcement Agency (NDLEA)

The NDLEA, historically focused on cannabis eradication and prosecution, faces a transitional role under medical legalization. The agency will maintain enforcement authority over illicit cultivation and recreational use while adapting to distinguish legal medical activities from criminal conduct. NDLEA Chairman Buba Marwa has publicly supported medical cannabis within strict regulatory bounds, according to agency statements, recognizing the distinction between controlled medical use and recreational consumption. The agency's cooperation is essential for preventing diversion of medical cannabis into illicit markets.

Federal Ministry of Health

The Ministry of Health provides policy guidance and coordinates between NAFDAC, medical professional organizations, and healthcare facilities. The ministry has advocated for evidence-based cannabis policy, emphasizing patient access and medical research. Under proposed legislation, the ministry would house the Cannabis Regulatory Commission, centralizing oversight and ensuring alignment with broader healthcare priorities.

National Assembly Legislative Champions

Senator Iroegbu Chuma and Representative Nnamdi Iro have led legislative efforts, sponsoring bills and building coalitions to overcome opposition. These lawmakers have framed medical cannabis as both a healthcare imperative and economic opportunity, appealing to colleagues across party lines. Their persistence through multiple legislative sessions has been instrumental in maintaining momentum despite conservative resistance.

Nigerian Medical Association

The Nigerian Medical Association, representing the country's physicians, has provided cautious support for medical cannabis legalization. The association has emphasized the need for clinical evidence, physician training, and patient safety protocols. Medical professionals' endorsement has lent credibility to legalization efforts, countering claims that cannabis lacks therapeutic value.

Agricultural Industry Stakeholders

Nigeria's agricultural sector views cannabis cultivation as a high-value crop opportunity. Organizations including the All Farmers Association of Nigeria have advocated for cultivation licensing frameworks that include smallholder farmers alongside large commercial operations. These groups emphasize cannabis's potential to generate rural employment and agricultural income diversification.

International Cannabis Companies

Canadian licensed producers, Israeli medical cannabis firms, and European pharmaceutical companies have engaged with Nigerian policymakers, offering technical expertise and signaling investment interest. Companies including Canopy Growth Corporation and Tikun Olam have conducted preliminary market assessments, positioning for potential partnerships with Nigerian entities once licensing begins.

Religious and Conservative Opposition

Religious organizations, particularly Christian and Muslim groups, have expressed concerns about cannabis legalization's moral implications. These groups distinguish between medical use, which some accept reluctantly, and any movement toward recreational legalization, which they uniformly oppose. Their influence in Nigerian society requires policymakers to emphasize strict medical-only frameworks and robust controls against recreational access.

Legal and Regulatory Framework

Nigeria's medical cannabis framework balances international treaty compliance, domestic pharmaceutical regulation, and agricultural licensing within a federalist structure that reserves drug policy to the federal government. The legal foundation rests on several layers of authority. The Constitution of the Federal Republic of Nigeria (1999, as amended) grants the federal government exclusive authority over drug policy through the Exclusive Legislative List, preventing states from independently legalizing cannabis. This centralization ensures uniform national standards but requires federal legislative action for policy change. The Indian Hemp Act of 1966 currently criminalizes all cannabis activities, imposing penalties ranging from imprisonment to fines. Medical cannabis legalization requires either repealing this statute or amending it to create exceptions for licensed medical activities. Proposed legislation takes the amendment approach, preserving criminal penalties for unlicensed activities while establishing regulated medical pathways. NAFDAC derives its regulatory authority from the NAFDAC Act (1993), which empowers the agency to regulate pharmaceuticals, including controlled substances. NAFDAC's 2022 Guidelines for Cannabis-Based Products for Medical Use establish product classifications, requiring cannabis medicines to meet pharmaceutical standards equivalent to other prescription drugs. Products must contain standardized cannabinoid concentrations, undergo stability testing, and include accurate labeling. The guidelines permit three product categories: cannabis-based pharmaceutical preparations (defined cannabinoid ratios), botanical cannabis products (whole-plant preparations), and synthetic cannabinoids. The proposed Cannabis Control Bill establishes a licensing framework with multiple categories. Cultivation licenses would authorize cannabis growing for medical purposes, with separate tiers for small-scale (under 1 hectare), medium-scale (1-10 hectares), and large-scale (over 10 hectares) operations. Processing licenses would permit extraction, manufacturing, and product formulation. Distribution licenses would authorize wholesale and pharmacy-level dispensing. Research licenses would enable clinical trials and scientific studies at universities and medical institutions. Security requirements mirror those for pharmaceutical opioids and other controlled substances. Licensed facilities must implement physical security measures including fencing, surveillance systems, and access controls. Product tracking from cultivation through patient dispensing would utilize a seed-to-sale monitoring system, likely adapted from models used in Canada and U.S. states. This tracking prevents diversion into illicit markets and ensures regulatory compliance. Physician prescription protocols require medical professionals to complete specialized training before recommending cannabis-based treatments. Qualifying conditions would initially include epilepsy, chronic pain, cancer-related symptoms, multiple sclerosis, and HIV/AIDS-related wasting syndrome, with provisions for adding conditions based on clinical evidence. Patients would register with NAFDAC, receiving identification cards authorizing pharmacy access. International treaty compliance remains paramount. The 1961 Single Convention on Narcotic Drugs permits cannabis for medical and scientific purposes under government licensing and control. Nigeria's framework aligns with these requirements by limiting legal cannabis to medical use, implementing strict licensing, and maintaining criminal penalties for recreational activities. The International Narcotics Control Board (INCB), which monitors treaty compliance, has accepted similar medical cannabis programs in other signatory nations. Import and export provisions recognize Nigeria's potential as both a cannabis medicine importer during program initiation and eventual exporter once domestic production scales. Import licenses would permit pharmaceutical companies to bring cannabis-based medicines into Nigeria for patient access before domestic cultivation reaches commercial scale. Export licenses would enable Nigerian producers to access international medical cannabis markets, particularly in Africa and Europe, generating foreign exchange revenue.

Market and Business Implications

Nigeria's medical cannabis market could reach $2.8 billion annually by 2030, attracting domestic and international investment while creating vertically integrated supply chains from cultivation through retail distribution. Market size projections vary but consistently indicate substantial economic potential. Prohibition Partners, a cannabis industry research firm, estimated in 2024 that Nigeria's medical cannabis market could reach $1.4 billion by 2028, assuming legalization proceeds. More optimistic projections from Arcview Market Research suggest $2.8 billion by 2030 if Nigeria captures regional export markets. These figures reflect Nigeria's large population, high prevalence of qualifying medical conditions, and potential as a low-cost cultivation jurisdiction. Cultivation economics favor Nigeria's entry into global cannabis supply chains. Labor costs significantly below those in Canada, Europe, and U.S. states provide competitive advantages. Land availability and tropical growing conditions enable year-round outdoor cultivation in many regions, reducing energy costs compared to indoor operations common in northern climates. However, infrastructure challenges including unreliable electricity, limited cold-chain logistics, and underdeveloped transportation networks require substantial capital investment. Licensed producer market structure will likely follow patterns seen in other emerging markets, with a mix of domestic agricultural companies, pharmaceutical firms, and international joint ventures. Canadian licensed producers have expressed interest in Nigerian partnerships, bringing cultivation expertise and access to international distribution channels. Israeli companies offer advanced genetics and precision agriculture technology. Domestic pharmaceutical manufacturers including Emzor Pharmaceutical Industries and May & Baker Nigeria could leverage existing regulatory relationships and distribution networks. Investment capital requirements vary by license category. Small-scale cultivation operations might require $200,000 to $500,000 for land preparation, security infrastructure, and initial operating capital. Large-scale operations with processing facilities could require $10 million to $50 million, necessitating institutional investment or international partnerships. Processing and manufacturing facilities require pharmaceutical-grade equipment, quality control laboratories, and trained personnel, with setup costs ranging from $5 million to $20 million depending on scale. Banking and financial services present challenges due to international banking regulations and correspondent banking relationships. Nigerian banks may hesitate to serve cannabis businesses due to concerns about U.S. dollar clearing systems and international compliance, despite domestic legality. This could force cannabis businesses toward cash operations or require development of specialized financial institutions, similar to credit unions serving U.S. cannabis businesses. Taxation frameworks remain under discussion. Proposed legislation includes cultivation taxes, excise taxes on finished products, and standard corporate income taxes. Revenue projections suggest medical cannabis could generate $150 million to $300 million in annual tax revenue once markets mature, providing funding for healthcare programs and regulatory oversight. Employment impacts extend beyond direct cultivation and processing jobs. Ancillary businesses including security services, testing laboratories, legal and accounting services, packaging suppliers, and specialized software providers would emerge. Educational institutions may develop cannabis science and business programs, creating training pathways for industry professionals. Export potential represents significant upside. Nigeria could supply medical cannabis to other African nations lacking cultivation capacity, positioning as a regional hub similar to Lesotho's role in southern Africa. European markets, particularly Germany with its large medical cannabis program, import substantial quantities from low-cost producers. Nigerian producers meeting EU-GMP (Good Manufacturing Practice) standards could access these markets, though achieving certification requires substantial quality system investments. Intellectual property considerations include plant genetics, extraction processes, and product formulations. International cannabis companies hold extensive patent portfolios that could create licensing requirements for Nigerian producers. Conversely, Nigeria could develop proprietary genetics adapted to tropical conditions, creating exportable intellectual property.

What Experts Say

Medical professionals, policy analysts, and industry experts view Nigeria's medical cannabis legalization as a significant healthcare and economic development opportunity requiring careful implementation to succeed. Dr. Babatunde Adeyemi, a neurologist at Lagos University Teaching Hospital, has advocated for cannabis-based epilepsy treatments, noting that many Nigerian patients lack access to effective medications. According to statements to Nigerian media, Adeyemi emphasized that cannabis-derived treatments like cannabidiol (CBD) have demonstrated efficacy in treatment-resistant epilepsy cases, potentially benefiting thousands of Nigerian children and adults who experience frequent seizures despite conventional medications. Professor Clement Adebamowo, an oncologist and epidemiologist at the University of Maryland with extensive Nigerian research experience, has called for robust clinical research as medical cannabis programs develop. Adebamowo has stated that while international evidence supports cannabis for certain conditions, Nigerian-specific research is needed to understand how genetic factors, concurrent medications, and local disease patterns affect treatment outcomes. Cannabis policy expert Steve Rolles, senior policy analyst at the Transform Drug Policy Foundation, has described Nigeria's approach as pragmatic, balancing medical access with social concerns about recreational use. According to Rolles, Nigeria's regulatory framework draws on international best practices while adapting to local conditions, potentially serving as a model for other African nations considering medical cannabis programs. Agricultural economist Dr. Ngozi Okonjo-Iweala, former Nigerian Finance Minister and current World Trade Organization Director-General, has not commented specifically on cannabis but has consistently advocated for agricultural diversification in Nigeria. Her broader policy positions suggest support for high-value crop development that generates rural employment and export revenue, criteria that cannabis cultivation could meet. International cannabis industry analysts view Nigeria as a high-potential but high-risk market. Prohibition Partners' 2024 Africa Cannabis Report identified Nigeria as the continent's largest potential market by population and economic size, but noted regulatory uncertainty, infrastructure challenges, and banking sector hesitancy as investment barriers. The report suggested that successful implementation could trigger broader West African legalization, while implementation failures could slow regional momentum. Medical cannabis patient advocates in Nigeria, operating through organizations like the Nigerian Cannabis Patients Alliance, have emphasized access and affordability concerns. These groups have called for pricing regulations to ensure medications remain affordable for average Nigerians, whose healthcare spending is predominantly out-of-pocket. They have also advocated for cultivation licenses that include smallholder farmers, preventing market concentration among large corporations. Religious leaders have offered mixed perspectives. Some Christian and Muslim clerics have accepted medical cannabis as distinct from recreational use, comparing it to morphine and other controlled medical substances derived from prohibited plants. Others maintain opposition to any cannabis legalization, viewing it as a gateway to broader drug acceptance. This division reflects broader Nigerian society's evolving but cautious attitudes toward cannabis policy reform.

What's Next

Nigeria's medical cannabis legalization timeline extends through late 2026 for legislative completion, followed by 12-18 months of regulatory implementation before licensed cultivation and patient access begin in 2028. The immediate legislative calendar includes several critical milestones. The Senate must complete third reading of the Cannabis Control Bill, requiring majority approval before transmission to the House of Representatives. The House will reconcile its Medical Cannabis Bill with the Senate version through a conference committee, producing unified legislation. Both chambers must then pass the reconciled bill before sending it to President Bola Tinubu for assent. Presidential approval is not guaranteed. President Tinubu has not publicly stated a position on medical cannabis, though his administration's economic diversification priorities suggest potential support. However, political considerations including religious constituency concerns and international relations could influence his decision. If Tinubu signs the legislation, implementation begins immediately. If he vetoes it, the National Assembly could override with a two-thirds majority in both chambers, though this outcome is uncertain. Assuming legislative success by late 2026, NAFDAC would begin accepting license applications in early 2027. The agency must finalize application forms, fee structures, and evaluation criteria. Initial licensing rounds would likely prioritize research institutions and pharmaceutical companies with existing regulatory relationships, followed by cultivation and processing licenses for commercial operators. Cultivation licensing would proceed in phases. Small-scale licenses for research and limited production might be issued by mid-2027, enabling pilot programs and genetics development. Large-scale commercial cultivation licenses would follow in late 2027 or early 2028, once regulatory systems are tested and refined. First harvests from licensed operations would occur 3-6 months after planting, depending on cultivation methods and strain selection. Product development and approval timelines depend on whether Nigeria permits imported cannabis medicines during domestic production scale-up. If imports are allowed, patients could access foreign-manufactured products by late 2027, pending NAFDAC product approvals. Domestically produced medicines would reach pharmacies by late 2028 or early 2029, once cultivation, processing, and product testing are complete. Physician training programs must be developed and delivered before prescriptions can be written. Medical schools and professional associations would create curricula covering cannabis pharmacology, qualifying conditions, dosing protocols, and adverse effect management. Training could begin in 2027, with certified physicians able to recommend cannabis by early 2028. Patient registry development requires database systems, identification card production, and privacy protections. NAFDAC would likely contract technology providers to build these systems, with patient enrollment beginning once physician certification and product availability align in 2028. International developments could accelerate or slow Nigeria's timeline. If neighboring countries including Ghana or Kenya legalize medical cannabis, competitive pressure might speed Nigerian implementation. Conversely, if early-adopting African nations experience implementation problems or diversion issues, Nigeria might proceed more cautiously. Economic factors including foreign investment flows and agricultural sector readiness will influence commercialization speed. If international cannabis companies commit substantial capital to Nigerian operations, production could scale rapidly. If investment is limited due to banking challenges or political uncertainty, market development would be slower. Long-term scenarios include potential recreational legalization discussions, though these are unlikely before 2030. Medical program performance, public opinion evolution, and international trends will determine whether Nigeria eventually considers adult-use legalization. More immediately, program expansion to include additional qualifying conditions, home cultivation for patients, and cannabis research funding could occur within 3-5 years of initial implementation. Regional integration through ECOWAS could create opportunities for cross-border medical cannabis commerce, with Nigeria potentially supplying neighboring countries. However, this requires harmonized regulations across member states, a complex process that could take years to achieve.

Further Reading

• National Agency for Food and Drug Administration and Control (NAFDAC) official website: https://www.nafdac.gov.ng
• National Drug Law Enforcement Agency (NDLEA) official website: https://ndlea.gov.ng
• Nigerian National Assembly legislative tracking: https://www.nassnig.org
• 1961 Single Convention on Narcotic Drugs full text: https://www.unodc.org/unodc/en/treaties/single-convention.html
• International Narcotics Control Board (INCB) annual reports: https://www.incb.org/incb/en/publications/annual-reports/annual-report.html
• Prohibition Partners Africa Cannabis Report 2024: https://prohibitionpartners.com/reports/
• World Health Organization Expert Committee on Drug Dependence cannabis review: https://www.who.int/medicines/access/controlled-substances/ecdd_40_meeting/en/
• Transform Drug Policy Foundation international cannabis policy resources: https://transformdrugs.org
• Nigerian Medical Association official statements: https://www.nigeriannma.org
• All Farmers Association of Nigeria: https://afan.org.ng